AI-generated analysis. Always verify with the original filing.
BioCorRx Inc. completed a stock exchange with insiders, acquiring 12.15% of subsidiary BioCorRx Pharmaceuticals' shares for 2,263,371 Parent Shares to advance its tax-free reorganization plan.
The stock exchange enables BioCorRx Inc. to increase control over its majority-owned subsidiary BioCorRx Pharmaceuticals, Inc., aligning with the company's Plan of Reorganization to meet Section 368(c) control requirements for a tax-free restructuring. Insiders, including the CEO, President, and a director, contributed their minority stakes representing 12.15% of the subsidiary's common stock, receiving restricted Parent Shares in return. This related-party transaction, pre-approved by the Board under the company's policy, avoids cash outlay and preserves liquidity while providing shareholders with equity upside and limited registration rights. The unregistered issuance relies on private placement exemptions, with Parent Shares bearing resale restrictions under Rule 144, reflecting the non-public nature of the deal among accredited insiders familiar with the company.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement.** Stock Exchange Agreement On March 26, 2026, BioCorRx Inc., a Nevada corporation (the “Company”), entered into a st
. The Parent Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) and are or will be, as the case may be, “restri
Financial Statements and Exhibits.** (d) Exhibits . The following documents are filed as exhibits to this current report on Form 8-K or incorporated by referenc
Material Agreement